FDA approved FUROSCIX ReadyFlow, a rapid subcutaneous auto-injector for IV-equivalent furosemide, enabling at-home treatment for fluid overload. Clinical data confirmed bioequivalence and safety, with broad U.S. launch planned in Q3 2026 and alignment with upcoming CMS incentives.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.